Mankind Pharma Ltd

Rivotril, the innovator/reference brand of clonazepam, is widely prescribed for the management of neurological and psychiatric conditions. Known as a textbook brand with a strong clinical legacy, the acquisition reinforces Mankind Pharma's presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio. The move aligns with Mankind Pharma's growing focus on chronic therapies, an area where the company has expanded steadily through new product launches, in-licensing partnerships, and portfolio additions across key therapeutic areas. Chronic therapies now contribute an increasing share to the company's overall business, enabling deeper engagement with specialists and key opinion leaders. Atish Majumdar, senior president, sales & marketing, Mankind Pharma Specialty Business, said, 'This acquisition is aligned with our strategic focus on strengthening our presence in chronic and specialty therapies. We see strong opportunities to build on this platform through potential line extensions, addressing the evolving needs of patients and physicians in the CNS therapy area. Leveraging our large field force and nationwide distribution network, we are well positioned to build the brand and support physicians in delivering better outcomes for patients across India.' Mankind Pharma plans to utilize its extensive distribution network and field force to expand access to Rivotril across healthcare institutions and prescribers. The company currently engages with over 5 lakh doctors in India, enabling strong prescription penetration across urban and semi-urban markets. Mankind Pharma is one of India's largest pharmaceutical companies, operating with a pan-India presence. The company manufactures a wide range of dosage forms, including tablets, capsules, syrups, vials, ampoules, blow-fill-seal products, soft and hard gels, eye drops, creams, contraceptives, and other over-the-counter products across 32 manufacturing facilities. It also maintains six dedicated R&D centers with more than 730 scientists, supporting a consistent track record of product innovation. The company reported a 7.5% rise in consolidated net profit of Rs 408.75 crore in Q3 FY26 as against Rs 380.23 crore posted in Q3 FY25. Net sales fell 11.5% YoY to Rs 3,567.20 crore in the quarter ended 31 December 2025. Powered by Capital Market - Live

Mankind Pharma has acquired the brand Rivotril from Roche for the Indian market, with exclusive rights to manufacture, market and distribute the product across the country. Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions. Often regarded as a Textbook brand in its category with a strong clinical legacy, Rivotril further strengthens Mankind Pharma's presence in the central nervous system (CNS) therapy segment and complements its existing neuro portfolio. The acquisition builds on Mankind Pharma's growing focus on chronic therapies, where the company has steadily expanded its presence through new launches, in-licensing partnerships and portfolio additions across key therapeutic areas. Chronic therapies now account for a rising share of the company's overall business as they continue to scale specialty segments and deepen engagement with specialists and key opinion leaders. Furthermore, the addition of Rivotril, an innovator brand with great recall amongst specialists, will strengthen its CNS portfolio and expand treatment options for patients managing neurological conditions. Powered by Capital Market - Live

Mankind Pharma has allotted 23,256 equity shares under ESOP on 16 March 2026. Post allotment, the paid up equity share capital has increased to 41,28,28,328 equity shares having face value of Re 1/- each. Powered by Capital Market - Live

Mankind Pharma Ltd gained for a third straight session today. The stock is quoting at Rs 2113.1, up 2.84% on the day as on 12:49 IST on the NSE. The benchmark NIFTY is up around 0.17% on the day, quoting at 25467.85. The Sensex is at 82264.76, up 0.05%. Mankind Pharma Ltd has gained around 0.9% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 5.38% in last one month and is currently quoting at 22632.05, up 1.45% on the day. The volume in the stock stood at 3.22 lakh shares today, compared to the daily average of 3.54 lakh shares in last one month. The benchmark March futures contract for the stock is quoting at Rs 2126.3, up 2.78% on the day. Mankind Pharma Ltd is down 7.89% in last one year as compared to a 12.96% jump in NIFTY and a 13.66% jump in the Nifty Pharma index.The PE of the stock is 47.98 based on TTM earnings ending December 25.Powered by Capital Market - Live

Net profit of Mankind Pharma rose 7.50% to Rs 408.75 crore in the quarter ended December 2025 as against Rs 380.23 crore during the previous quarter ended December 2024. Sales rose 11.52% to Rs 3567.20 crore in the quarter ended December 2025 as against Rs 3198.79 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales3567.203198.79 12 OPM %25.7725.51 - PBDT838.19675.50 24 PBT615.59488.33 26 NP408.75380.23 8 Powered by Capital Market - Live

Securities in F&O Ban: Sammaan Capital shares are banned from F&O trading on 04 February 2026. Result Today: Archean Chemical Industries, Apollo Tyres, Aptus Value Housing Finance India, Aurionpro Solutions, Automotive Axles, Avalon Technologies, Bajaj Finserv, Bajaj Holdings & Investment, Carysil, CCL Products (India), Century Plyboards (India), Cera Sanitaryware, Cummins India, Devyani International, Emami, Emcure Pharmaceuticals, Eureka Forbes, Force Motors, Gallantt Ispat, Greenply Industries, Hexaware Technologies, Inventurus Knowledge Solutions, Jain Irrigation Systems, Jaiprakash Power Ventures, JSW Cement, Jubilant Ingrevia, Kalpataru Projects International, Lloyds Engineering Works, Global Health, Metropolis Healthcare, NHPC, Parag Milk Foods, Apeejay Surrendra Park Hotels, Pokarna, Quality Power Electrical Equipments, Redington, RITES, Rane (Madras), Keystone Realtors, Saatvik Green Energy, Sammaan Capital, Shipping Corporation of India Land and Assets, Tata Power Company, Transport Corporation of India, TeamLease Services, Tube Investments of India, Timken India, Tamilnad Mercantile Bank, Trent, Welspun Enterprises, Westlife Foodworld, Wonderla Holidays and Xpro India will announce their quarterly earnings today. Stocks to Watch: Bajaj Finance reported 6.33% decline in consolidated net profit to Rs 3,977.85 crore in Q3 FY26 compared with Rs 4,246.54 crore in Q3 FY25. Total revenue from operations jumped 17.63% YoY to Rs 21,213.89 crore in Q3 FY26. Mankind Pharma reported a 7.6% year-on-year increase in consolidated net profit to Rs 409 crore, driven by an 11.5% rise in revenue from operations to Rs 3,567 crore in Q3 FY26, compared with Q3 FY25. Godrej Agrovet posted a 3% year-on-year growth in consolidated net profit to Rs 115 crore, while revenue increased 11% to Rs 2,718 crore in Q3 FY26 over Q3 FY25. Rubucon Research reported 91.2% jump in consolidated net profit to Rs 72.8 crore on 51.7% increase in revenue from operations to Rs 475.5 crore in Q3 FY26 over Q3 FY25. Aditya Birla Capital's consolidated net profit jumped 33.48% to Rs 945.02 crore on 27.4% increase in revenue from operations to Rs 11952.09 crore in Q3 FY36 over Q2 FY25.Powered by Capital Market - Live

Mankind Pharma announced that ICRA has assigned the rating ICRA AA+; Stable / ICRA A1+ for debt facilities of the company including non-convertible debentures. The rating on commercial paper of ICRA A1+ has been withdrawn. Powered by Capital Market - Live

Mankind Pharma will hold a meeting of the Board of Directors of the Company on 3 February 2026.Powered by Capital Market - Live

Mankind Pharma Ltd is up for a fifth straight session today. The stock is quoting at Rs 2228.7, up 1.94% on the day as on 12:44 IST on the NSE. The benchmark NIFTY is up around 0.01% on the day, quoting at 26175.65. The Sensex is at 85535.57, down 0.04%. Mankind Pharma Ltd has gained around 0.27% in last one month. Meanwhile, Nifty Pharma index of which Mankind Pharma Ltd is a constituent, has gained around 1.82% in last one month and is currently quoting at 22927.9, down 0.11% on the day. The volume in the stock stood at 3.36 lakh shares today, compared to the daily average of 4.94 lakh shares in last one month. The benchmark December futures contract for the stock is quoting at Rs 2231.3, up 2.1% on the day. Mankind Pharma Ltd is down 23.43% in last one year as compared to a 10.32% jump in NIFTY and a 1.52% jump in the Nifty Pharma index.The PE of the stock is 54.2 based on TTM earnings ending September 25.Powered by Capital Market - Live

Mankind Pharma has allotted 46,582 equity shares under ESOP on 26 November 2025. With this allotment, the paid up equity share capital has increased to 41,28,05,072 equity shares having face value of Re 1/- each. Powered by Capital Market - Live